PH12016502479A1 - Formulated receptor polypeptides and related methods - Google Patents
Formulated receptor polypeptides and related methodsInfo
- Publication number
- PH12016502479A1 PH12016502479A1 PH12016502479A PH12016502479A PH12016502479A1 PH 12016502479 A1 PH12016502479 A1 PH 12016502479A1 PH 12016502479 A PH12016502479 A PH 12016502479A PH 12016502479 A PH12016502479 A PH 12016502479A PH 12016502479 A1 PH12016502479 A1 PH 12016502479A1
- Authority
- PH
- Philippines
- Prior art keywords
- related methods
- formulated
- receptor polypeptides
- disclosed
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Disclosed herein is an activin receptor IIB-based composition and related methods of use, e.g., to treat solid tumors. Also disclosed are methods of manufacturing the compound and formulation.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462012104P | 2014-06-13 | 2014-06-13 | |
US201462047995P | 2014-09-09 | 2014-09-09 | |
US201462058789P | 2014-10-02 | 2014-10-02 | |
US201562142812P | 2015-04-03 | 2015-04-03 | |
PCT/US2015/035818 WO2015192127A2 (en) | 2014-06-13 | 2015-06-15 | Formulated receptor polypeptides and related methods |
Publications (1)
Publication Number | Publication Date |
---|---|
PH12016502479A1 true PH12016502479A1 (en) | 2017-04-10 |
Family
ID=54834575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH12016502479A PH12016502479A1 (en) | 2014-06-13 | 2016-12-12 | Formulated receptor polypeptides and related methods |
Country Status (19)
Country | Link |
---|---|
US (1) | US20170202909A1 (en) |
EP (1) | EP3155008B1 (en) |
JP (1) | JP2017519009A (en) |
KR (1) | KR20170035891A (en) |
CN (1) | CN107074931A (en) |
AP (1) | AP2016009647A0 (en) |
AU (1) | AU2015274293A1 (en) |
BR (1) | BR112016029211A2 (en) |
CA (1) | CA2952231A1 (en) |
CL (1) | CL2016003191A1 (en) |
EA (1) | EA201692568A1 (en) |
IL (1) | IL249373A0 (en) |
MX (1) | MX2016016281A (en) |
PE (1) | PE20170471A1 (en) |
PH (1) | PH12016502479A1 (en) |
SG (1) | SG11201610432UA (en) |
TN (1) | TN2016000551A1 (en) |
TW (1) | TW201625675A (en) |
WO (1) | WO2015192127A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME00380B (en) | 2005-11-23 | 2011-10-10 | Acceleron Pharma Inc | Activin-actriia antagonists and uses for promoting bone growth |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
MX2009008222A (en) | 2007-02-01 | 2009-10-12 | Acceleron Pharma Inc | Activin-actriia antagonists and uses for treating or preventing breast cancer. |
TWI432449B (en) | 2007-02-02 | 2014-04-01 | Acceleron Pharma Inc | Variants derived from actriib and uses therefor |
TW201808334A (en) | 2007-02-09 | 2018-03-16 | 艾瑟勒朗法瑪公司 | Pharmaceutical composition comprising an ActRIIa-Fc fusion protein; use of an ActRIIa-Fc fusion protein for treatment or prevention of cancer-related bone loss; use of an ActRIIa-Fc fusion protein for the treatment or prevention of multiple myeloma |
US7960343B2 (en) | 2007-09-18 | 2011-06-14 | Acceleron Pharma Inc. | Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
DK3750552T3 (en) | 2008-08-14 | 2023-07-24 | Acceleron Pharma Inc | GDF TRAPS |
JP5912078B2 (en) | 2009-06-08 | 2016-04-27 | アクセルロン ファーマ, インコーポレイテッド | Methods for increasing thermogenic adipocytes |
JP2012529294A (en) | 2009-06-12 | 2012-11-22 | アクセルロン ファーマ, インコーポレイテッド | Cleaved ActRIIB-Fc fusion protein |
US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
JP2014502260A (en) | 2010-11-08 | 2014-01-30 | アクセルロン ファーマ, インコーポレイテッド | ACTRIIA binders and uses thereof |
RU2678117C2 (en) | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Activin-actrii antagonists and uses thereof for treating bone and other disorders |
EA201591423A1 (en) | 2013-02-01 | 2016-01-29 | Санта Мария Биотерапевтикс, Инк. | INTRODUCTION OF ANTIBODIES TO ACTIVINE-A TO PATIENTS |
MA40008A (en) | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | ANTAGONIST ACTRII FOR THE TREATMENT AND PREVENTION OF SKIN ULCER IN A SUBJECT WITH ANEMIA |
DK3286206T3 (en) | 2015-04-22 | 2021-05-03 | Biogen Ma Inc | UNKNOWN HYBRID ACTRIIB-LIGAND-TRAP PROTEINS FOR THE TREATMENT OF MUSCLE WIND DISEASES |
AU2017357935B2 (en) | 2016-11-10 | 2022-04-28 | Keros Therapeutics, Inc. | Activin receptor type IIa variants and methods of use thereof |
US11932699B2 (en) | 2017-09-07 | 2024-03-19 | Jcr Pharmaceuticals Co., Ltd. | Aqueous pharmaceutical composition |
KR20200085832A (en) | 2017-11-09 | 2020-07-15 | 케로스 테라퓨틱스, 인크. | Activin receptor type IIA variants and methods of use thereof |
JP2021518745A (en) | 2018-01-12 | 2021-08-05 | ケロス セラピューティクス インコーポレイテッドKeros Therapeutics,Inc. | Activin type IIB receptor mutants and how to use them |
CA3108920A1 (en) * | 2018-08-29 | 2020-03-05 | Translate Bio, Inc. | Improved process of preparing mrna-loaded lipid nanoparticles |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
JP2877509B2 (en) | 1989-05-19 | 1999-03-31 | アムジエン・インコーポレーテツド | Metalloproteinase inhibitors |
PT1129190E (en) | 1998-11-13 | 2007-08-08 | Immunex Corp | Human tslp dna and polypeptides |
JP4038118B2 (en) | 2002-11-29 | 2008-01-23 | 株式会社コガネイ | Fluid pressure cylinder |
US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
US7947646B2 (en) * | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
SG2013054218A (en) * | 2008-01-15 | 2014-10-30 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
EA201100832A1 (en) * | 2008-11-26 | 2011-12-30 | Амген Инк. | OPTIONS OF POLYPEPTIDES OF ACTIVIN IIB RECEPTOR AND THEIR APPLICATION |
RU2600847C2 (en) * | 2010-05-10 | 2016-10-27 | Интас Биофармасьютикалс Лимитед | Liquid composition of polypeptides containing fc domain of immunoglobulin |
JP5782185B2 (en) | 2012-06-01 | 2015-09-24 | 日本電信電話株式会社 | Packet transfer processing method and packet transfer processing device |
EA201591423A1 (en) * | 2013-02-01 | 2016-01-29 | Санта Мария Биотерапевтикс, Инк. | INTRODUCTION OF ANTIBODIES TO ACTIVINE-A TO PATIENTS |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
WO2016205370A1 (en) * | 2015-06-15 | 2016-12-22 | Santa Maria Biotherapeutics, Inc. | Methods of using activin receptor iib-based proteins |
-
2015
- 2015-06-15 AU AU2015274293A patent/AU2015274293A1/en not_active Abandoned
- 2015-06-15 AP AP2016009647A patent/AP2016009647A0/en unknown
- 2015-06-15 EP EP15805829.7A patent/EP3155008B1/en active Active
- 2015-06-15 WO PCT/US2015/035818 patent/WO2015192127A2/en active Application Filing
- 2015-06-15 CA CA2952231A patent/CA2952231A1/en active Pending
- 2015-06-15 KR KR1020177001016A patent/KR20170035891A/en unknown
- 2015-06-15 PE PE2016002711A patent/PE20170471A1/en not_active Application Discontinuation
- 2015-06-15 MX MX2016016281A patent/MX2016016281A/en unknown
- 2015-06-15 TW TW104119310A patent/TW201625675A/en unknown
- 2015-06-15 CN CN201580043173.4A patent/CN107074931A/en active Pending
- 2015-06-15 SG SG11201610432UA patent/SG11201610432UA/en unknown
- 2015-06-15 US US15/316,767 patent/US20170202909A1/en not_active Abandoned
- 2015-06-15 JP JP2016572730A patent/JP2017519009A/en active Pending
- 2015-06-15 BR BR112016029211A patent/BR112016029211A2/en not_active Application Discontinuation
- 2015-06-15 EA EA201692568A patent/EA201692568A1/en unknown
- 2015-06-15 TN TN2016000551A patent/TN2016000551A1/en unknown
-
2016
- 2016-12-04 IL IL249373A patent/IL249373A0/en unknown
- 2016-12-12 PH PH12016502479A patent/PH12016502479A1/en unknown
- 2016-12-13 CL CL2016003191A patent/CL2016003191A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN107074931A (en) | 2017-08-18 |
SG11201610432UA (en) | 2017-01-27 |
TN2016000551A1 (en) | 2018-04-04 |
WO2015192127A3 (en) | 2016-03-17 |
AU2015274293A1 (en) | 2017-02-02 |
MX2016016281A (en) | 2017-03-31 |
PE20170471A1 (en) | 2017-05-14 |
EP3155008A4 (en) | 2018-05-16 |
CL2016003191A1 (en) | 2017-11-10 |
JP2017519009A (en) | 2017-07-13 |
AP2016009647A0 (en) | 2016-12-31 |
EP3155008B1 (en) | 2020-08-26 |
KR20170035891A (en) | 2017-03-31 |
BR112016029211A2 (en) | 2018-01-30 |
US20170202909A1 (en) | 2017-07-20 |
EA201692568A1 (en) | 2017-05-31 |
WO2015192127A2 (en) | 2015-12-17 |
EP3155008A2 (en) | 2017-04-19 |
TW201625675A (en) | 2016-07-16 |
IL249373A0 (en) | 2017-02-28 |
CA2952231A1 (en) | 2015-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016502479A1 (en) | Formulated receptor polypeptides and related methods | |
MX2018014154A (en) | Modulatory polynucleotides. | |
MX2017006217A (en) | Modulatory polynucleotides. | |
PH12017500408B1 (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
ZA201700737B (en) | Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer | |
MY192927A (en) | Fused bicyclic compounds for the treatment of disease | |
MX2018006217A (en) | Apelin receptor agonists and methods of use. | |
PH12017500660A1 (en) | Novel compositions, uses and methods for making them | |
PH12016501441A1 (en) | Chimeric alkaline phosphate-like proteins | |
MX2017008456A (en) | Fused bicyclic compounds for the treatment of disease. | |
MX2018006632A (en) | Bicyclic inhibitors of pad4. | |
AU2015287674B2 (en) | Topical antiviral compositions and methods of using the same | |
MX2016010216A (en) | Solid pharmaceutical compositions of androgen receptor antagonists. | |
MX2016009590A (en) | Apilimod compositions and methods for using same. | |
MX2017008390A (en) | Alkoxysilane-functionalized and allophanate-functionalized urethanes. | |
MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
SG10201900598TA (en) | Factor viii formulation | |
MX2018005987A (en) | Heterocyclic compounds for the treatment of disease. | |
EP3169405A4 (en) | Methods, compounds, and compositions for the treatment of musculoskeletal diseases | |
MX2017012342A (en) | Fused bicyclic compounds for the treatment of disease. | |
MX2016004078A (en) | Hiv treatment formulation of atazanavir and cobicistat. | |
MX2019014861A (en) | Substituted quinolinycyclohexylpropanamide compounds and improved methods for their preparation. | |
IN2014CH00304A (en) | ||
MX2018014034A (en) | Fused bicyclic compounds for the treatment of disease. | |
MX2017017119A (en) | High concentration formulation. |